canertinib has been researched along with Exanthem in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bycott, P; Cunningham, C; Eiseman, I; Lenehan, PF; Nemunaitis, J; Olson, SC; Schlicht, M; Senzer, N; Shin, DM; Williams, A; Zentgraff, R; Zinner, RG | 1 |
| Bonomi, PD; Butts, CA; Chiappori, AA; Cohen, RB; Crino, L; Dasse, K; Eiseman, IA; Jänne, PA; Lenehan, PF; Olson, SS; Sheeran, M; von Pawel, J; Yeap, BY | 1 |
2 trial(s) available for canertinib and Exanthem
| Article | Year |
|---|---|
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Diarrhea; Drug Administration Schedule; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Protein-Tyrosine Kinases | 2005 |
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Survival Rate | 2007 |